AAHA issues new canine diabetes guidelines with CGM focus
Bottom line
The American Animal Hospital Association has released its 2026 Diabetes Management Guidelines for Dogs, updating recommendations on diagnosis, insulin treatment, monitoring, troubleshooting, diet, and client education for canine diabetes care. The new guidance reflects two major shifts in practice: broader use of continuous glucose monitors and updated discussion of long-acting insulins, including options that may allow once-daily dosing in some dogs. AAHA also split its diabetes guidance into separate canine and feline documents for the first time, citing important species differences in how diabetes presents and is managed. (aaha.org)
Why it matters: For veterinary professionals, the update gives primary care teams a more current framework for managing a disease that still depends on long-term follow-up, realistic treatment goals, and strong communication with pet parents. AAHA emphasizes that most diabetic dogs have absolute insulin deficiency and require lifelong insulin therapy, but that good outcomes are achievable when teams focus on control of clinical signs, practical monitoring, and individualized treatment plans rather than chasing tight glycemic control in every case. The guidelines also package that advice into algorithms, discharge tools, and monitoring resources that may help standardize care across the hospital team. (aaha.org)
What to watch: Expect clinics to take a closer look at CGM workflows, insulin-selection protocols, and how they educate pet parents about long-term diabetic care. (aaha.org)
Key facts
- Organization
- American Animal Hospital Association
- Guideline
- 2026 Diabetes Management Guidelines for Dogs
- Release date
- September 1, 2026
- Scope
- First canine-only diabetes guideline from AAHA
- Key update
- Broader use of continuous glucose monitors
- Insulin update
- Long-acting insulins, including degludec and glargine U-300
- Species difference
- Dogs typically have permanent beta cell loss and absolute insulin deficiency
- Primary treatment goal
- Control of clinical signs
- Monitoring note
- Dogs can be considered well controlled if polyuria, polydipsia, and polyphagia are absent and body weight is stable or increasing
The American Animal Hospital Association on September 1, 2026, released its 2026 Diabetes Management Guidelines for Dogs, marking AAHA’s first canine-only diabetes guideline and its first major canine diabetes update since the earlier combined dog-and-cat guidance. The document is aimed at step-by-step decision support for diagnosis, treatment, monitoring, dietary management, and troubleshooting, with a strong focus on changes driven by continuous glucose monitoring and newer insulin strategies. (aaha.org)
The split from a single cross-species guideline into separate canine and feline documents is one of the clearest signals of what has changed. AAHA says the move reflects the fact that diabetes behaves differently in dogs and cats. In dogs, the disease is typically characterized by permanent beta cell loss and absolute insulin deficiency, which means insulin therapy remains the foundation of care. That species-specific framing matters because it shapes expectations around remission, monitoring, and long-term management from the first client conversation onward. (aaha.org)
The practical updates center on tools and protocols that have become more accessible in recent years. AAHA highlights continuous glucose monitors as a major advance, and the insulin treatment section notes that CGM placement is recommended when starting a basal insulin so clinicians can more quickly determine the appropriate dose and whether a dog needs every-12-hour or every-24-hour administration. The guidelines also incorporate long-acting insulins such as degludec and glargine U-300, reflecting growing interest in regimens that may reduce dosing burden for some pet parents compared with the twice-daily schedules long considered standard. (aaha.org)
AAHA’s summary materials also underscore a more pragmatic treatment philosophy. The organization states that the primary goal of treating canine diabetes mellitus is control of clinical signs, and that tight glycemic control is rarely achievable with twice-daily intermediate-acting insulin alone. Its general monitoring guidance says dogs can still be considered well controlled when polyuria, polydipsia, and polyphagia are absent and body weight is stable or increasing, even if brief periods of marked hyperglycemia occur. That framing may help teams align medical decision-making with quality of life, adherence, and the day-to-day realities of general practice. (aaha.org)
In comments released with the announcement, task force member Audrey K. Cook said care for diabetic dogs has changed dramatically because of inexpensive CGMs and a better understanding of how to use long-acting insulins. AAHA Chief Medical Officer Jessica Vogelsang said the organization was especially excited to separate canine and feline guidance for the first time. While independent expert reaction appears limited so far, the release itself suggests AAHA sees this as a practice-facing update designed for immediate use by primary care teams, not just specialists. That’s also reflected in the companion tools posted alongside the guideline, including discharge templates, glucose-curve interpretation aids, and technician-focused resources. (aaha.org)
Why it matters: For veterinarians, technicians, and practice leaders, this is less about a headline-grabbing therapeutic breakthrough and more about a meaningful update to workflow and case management. CGM adoption, if it continues to expand, could change how clinics initiate insulin, assess control, and troubleshoot difficult cases. The guidance may also support more nuanced conversations with pet parents about what successful management looks like, especially when perfect glucose numbers aren’t realistic. In that sense, the guideline could help reduce overtreatment, improve consistency across teams, and make diabetic care more sustainable for both clinics and families. Those operational effects may be as important as the pharmacology updates themselves. This is an inference based on AAHA’s emphasis on algorithms, monitoring strategy, and client education tools. (aaha.org)
Another point worth noting is industry support. AAHA says the guideline was developed with support from Adapet Medical, Boehringer Ingelheim, Dechra, and Merck Animal Health. That does not negate the clinical value of the document, but it’s relevant context for readers evaluating how quickly newer monitoring devices and insulin products may move into broader use. As with any guideline, uptake will likely depend on cost, staff training, access to devices, and how comfortable individual practices are with changing established diabetic protocols. (aaha.org)
What to watch: The next signal will be adoption in general practice, especially whether clinics revise diabetic intake protocols, add CGM-based monitoring pathways, and shift more cases toward long-acting insulin strategies over the coming year. (aaha.org)